Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
暂无分享,去创建一个
T. Habuchi | C. Ohyama | M. Saito* | Ryohei Yamamoto | S. Hatakeyama | S. Narita | K. Numakura | A. Koizumi | S. Kashima | T. Nara | Y. Muto | Mizuki Kobayashi | Y. Sekine | Hajime Sasagawa | M. Saito*
[1] C. Porta,et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.
[2] J. Aerts,et al. Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy , 2021, Cancers.
[3] H. Cordell,et al. A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? , 2021, Cancers.
[4] L. Karabon,et al. Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk , 2021, Frontiers in Immunology.
[5] L. Pickering,et al. Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma , 2020, Cancers.
[6] R. Zdrojowy,et al. SNP-SNP Interaction in Genes Encoding PD-1/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma , 2020, Cancers.
[7] H. Miyake,et al. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data , 2020, International Journal of Clinical Oncology.
[8] M. Merl,et al. The impact of corticosteroid use during anti-PD1 treatment , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[9] C. Porta,et al. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. , 2020, Clinical genitourinary cancer.
[10] T. Habuchi,et al. Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes , 2020, International Journal of Clinical Oncology.
[11] A. Vecchione,et al. Reduced PD-1 expression on circulating follicular and conventional FOXP3+ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children , 2020 .
[12] M. Miyazato,et al. A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient , 2019, Urology case reports.
[13] T. Habuchi,et al. Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis. , 2019, Molecular and clinical oncology.
[14] Kazuhiko Yoshida,et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. , 2019, Urologic oncology.
[15] P. Catalano,et al. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial , 2019, Clinical Cancer Research.
[16] S. Sleijfer,et al. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients , 2018, British Journal of Cancer.
[17] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[18] Arash Salmaninejad,et al. PD-1 and cancer: molecular mechanisms and polymorphisms , 2018, Immunogenetics.
[19] A. Sharpe,et al. The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.
[20] M. Fukuoka,et al. Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. , 2017, Immunotherapy.
[21] Shinya Yamamoto,et al. Biomarkers to predict prognosis and response to checkpoint inhibitors , 2017, International Journal of Clinical Oncology.
[22] Young Hak Kim,et al. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients , 2017, Scientific Reports.
[23] Zhengwen Liu,et al. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma , 2016, Medicine.
[24] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[25] J. Terasaki,et al. Low programmed cell death‐1 (PD‐1) expression in peripheral CD4+ T cells in Japanese patients with autoimmune type 1 diabetes , 2015, Clinical and experimental immunology.
[26] Qianqian Zhu,et al. microRNA-4717 differentially interacts with its polymorphic target in the PD1 3′ untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases , 2015, Oncotarget.
[27] Sai Lou,et al. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. , 2010, Human immunology.
[28] B. Guillonneau,et al. Renal cell carcinoma in young and old patients--is there a difference? , 2008, The Journal of urology.
[29] R. Yamada,et al. Ethnic differences in allele frequency of autoimmune-disease-associated SNPs , 2005, Journal of Human Genetics.
[30] R. Jonsson,et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans , 2002, Nature Genetics.
[31] D. Bonaduce,et al. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. , 2018, Current medicinal chemistry.
[32] R. Herbst,et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.
[33] Fengchun Zhang,et al. The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review , 2015, Rheumatology International.
[34] O. Karadag,et al. PDCD1 polymorphisms are not associated with Takayasu's arteritis in Turkey. , 2012, Clinical and experimental rheumatology.